Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.32 |
| ▸ | OPRL1 | P41146 | 5/20 | 0.32 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.31 |
| ▸ | RARB | P10826 | 3/20 | 0.31 |
| ▸ | RARA | P10276 | 2/20 | 0.31 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.31 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.31 |
| ▸ | RARG | P13631 | 1/20 | 0.31 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.30 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.30 |
| ▸ | FPR2 | P25090 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20407558 | 0.94 | PPARG (0.31) | FFAR4DGAT1PPARG | |
| SCHEMBL20313595 | 0.93 | FFAR4 (0.35) | FFAR4DGAT1PPARGOPRL1PTGDR | |
| SCHEMBL20313594 | 0.91 | PPARG (0.33) | PPARGPTPN11FPR2 | |
| SCHEMBL20313587 | 0.90 | PPARG (0.33) | PPARGFPR2 | |
| SCHEMBL19854666 | 0.89 | FFAR4 (0.34) | FFAR4DGAT1OPRL1RARBRARA | |
| SCHEMBL19853859 | 0.89 | CYP2C9 (0.36) | DGAT1PPARGPTPN11FPR2 | |
| SCHEMBL20313592 | 0.89 | CYP2C9 (0.36) | DGAT1PPARGPTPN11FPR2 | |
| SCHEMBL19854221 | 0.88 | RARB (0.34) | FFAR4DGAT1OPRL1RARBRARA | |
| SCHEMBL19853846 | 0.88 | CYP2C9 (0.37) | DGAT1PPARGPTPN11FPR2 | |
| SCHEMBL19855073 | 0.87 | FFAR4 (0.35) | FFAR4DGAT1OPRL1PTGDRPTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210214615-A1 | LIQUID CRYSTAL DISPLAY DEVICE AND DISPLAY UNIT | JNC CORPORATION (JP) | 2021-07-15 | — | — | US | disclosed |
| US-20180179443-A1 | POLYMERIZABLE POLAR COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2018-06-28 | — | — | US | disclosed |
| US-20180179443-A1 | POLYMERIZABLE POLAR COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2018-06-28 | — | — | US | disclosed |
| WO-2018025974-A1 | LIQUID-CRYSTAL DISPLAY ELEMENT AND DISPLAY DEVICE | JNC株式会社 | 2018-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180179443-A1 | POLYMERIZABLE POLAR COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | C1S, CCND1, C5 | FFAR4 1865/4885DGAT1 2150/4885PPARG 2686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.